Getting personal with neoantigen-based therapeutic cancer vaccines.

Cancer Immunol Res
Authors
Keywords
Abstract

Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These "neoantigens" should provide highly specific targets for antitumor immunity. Although many challenges remain in producing and testing neoantigen-based vaccines customized for each patient, a neoantigen vaccine offers a promising new approach to induce highly focused antitumor T cells aimed at eradicating cancer cells.

Year of Publication
2013
Journal
Cancer Immunol Res
Volume
1
Issue
1
Pages
11-5
Date Published
2013 Jul
ISSN
2326-6074
DOI
10.1158/2326-6066.CIR-13-0022
PubMed ID
24777245
PubMed Central ID
PMC4033902
Links
Grant list
1R01CA155010-02 / CA / NCI NIH HHS / United States
5 R01 HL103532-03 / HL / NHLBI NIH HHS / United States
R01 CA155010 / CA / NCI NIH HHS / United States